What we're reading, September 15, 2016: A United Nations panel challenges the market-based approach to drug research and development; an FDA panel recommends removing a serious health warning from Chantix's label; and older patients may want to wait to get their flu shot.
The United Nations has released a report that challenges the market-based approach to drug research and development. According to Reuters, a panel set up last year recommends de-linking R&D costs and drug prices in some areas, such as tropical diseases and new antibiotics to fight “superbugs.” The report suggests a process for governments to negotiate agreements and attacks tactics by Western governments that are used to stop poorer countries from overriding drug patents under World Trade organization rules.
An FDA panel has recommended removing a serious warning about neuropsychiatric side effects from Chantix’s product labeling. The decision is a win for Pfizer, which will be able to widen the market for the smoking cessation pill, reported STAT. The drug maker has been trying to get the warning removed for 2 years. The panel made its decision based on a study that found Chantix does not appear to increase the risk of suicidal behavior, even though an FDA medical team voiced its doubts regarding the study.
While pharmacy chains are already calling for patients to get their flu shots, people may want to wait. While getting the flu shot early is better than not getting it at all, it’s unclear how long the vaccine’s immunity lasts in a person’s system, according to Kaiser Health News. In particular, the protective effects of the vaccine may wear off faster for people older than the age of 65. Flu activity generally doesn’t peak until January or February.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More